SCHEMBL13628292

SCHEMBL13628292

COc1ccc(-c2ccc3c(c2)N(Cc2cc(F)cc4c2OCOC4)C(=O)/C3=N\O)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.43
MAPK8 P45983 1/20 0.35
EPHA2 P29317 1/20 0.34
KDR P35968 1/20 0.34
EPHB4 P54760 1/20 0.34
NPC1 O15118 1/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
GALR3 O60755 1/20 0.33
NR2F2 P24468 1/20 0.33
KDM4E B2RXH2 2/20 0.33
MAPK1 P28482 1/20 0.33
LTC4S Q16873 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
ABCB1 P08183 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
THRB P10828 1/20 0.32
CYP19A1 P11511 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628288 0.92 TSHR (0.36) TSHRMAPK8EPHA2KDREPHB4
SCHEMBL13628295 0.89 POLB (0.36) TSHRMAPK8NPC1POLBRAB9A
SCHEMBL13628065 0.89 NPC1 (0.37) TSHRMAPK8NPC1POLBRAB9A
SCHEMBL13628290 0.88 POLB (0.34) TSHRMAPK8NPC1POLBRAB9A
SCHEMBL13628077 0.88 TSHR (0.38) TSHRMAPK8EPHA2KDREPHB4
SCHEMBL13910801 0.87 POLB (0.36) TSHRMAPK8NPC1POLBRAB9A
SCHEMBL13628296 0.87 POLB (0.34) TSHRMAPK8NPC1POLBRAB9A
SCHEMBL13628289 0.87 ALDH1A1 (0.37) TSHRMAPK8NPC1POLBRAB9A
SCHEMBL13628264 0.86 POLB (0.36) TSHRMAPK8NPC1POLBRAB9A
SCHEMBL13628070 0.86 NPC1 (0.36) TSHRMAPK8NPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 TSHR 4286/4885MAPK8 58/4885EPHA2 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.